BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 11259625)

  • 1. P-glycoprotein limits oral availability, brain, and fetal penetration of saquinavir even with high doses of ritonavir.
    Huisman MT; Smit JW; Wiltshire HR; Hoetelmans RM; Beijnen JH; Schinkel AH
    Mol Pharmacol; 2001 Apr; 59(4):806-13. PubMed ID: 11259625
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessing safety and efficacy of directed P-glycoprotein inhibition to improve the pharmacokinetic properties of saquinavir coadministered with ritonavir.
    Huisman MT; Smit JW; Wiltshire HR; Beijnen JH; Schinkel AH
    J Pharmacol Exp Ther; 2003 Feb; 304(2):596-602. PubMed ID: 12538811
    [TBL] [Abstract][Full Text] [Related]  

  • 3. P-glycoprotein and cytochrome P450 3A act together in restricting the oral bioavailability of paclitaxel.
    Hendrikx JJ; Lagas JS; Rosing H; Schellens JH; Beijnen JH; Schinkel AH
    Int J Cancer; 2013 May; 132(10):2439-47. PubMed ID: 23090875
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Variation in oral clearance of saquinavir is predicted by CYP3A5*1 genotype but not by enterocyte content of cytochrome P450 3A5.
    Mouly SJ; Matheny C; Paine MF; Smith G; Lamba J; Lamba V; Pusek SN; Schuetz EG; Stewart PW; Watkins PB
    Clin Pharmacol Ther; 2005 Dec; 78(6):605-18. PubMed ID: 16338276
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of saquinavir/ritonavir on P-glycoprotein activity in healthy volunteers using digoxin as a probe.
    Schmitt C; Kaeser B; Riek M; Bech N; Kreuzer C
    Int J Clin Pharmacol Ther; 2010 Mar; 48(3):192-9. PubMed ID: 20197013
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of the pharmacokinetic boosting effects of ritonavir on oral bioavailability of drugs in mice.
    Tomaru A; Takeda-Morishita M; Banba H; Takayama K
    Drug Metab Pharmacokinet; 2013; 28(2):144-52. PubMed ID: 22971642
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanisms of pharmacokinetic enhancement between ritonavir and saquinavir; micro/small dosing tests using midazolam (CYP3A4), fexofenadine (p-glycoprotein), and pravastatin (OATP1B1) as probe drugs.
    Ieiri I; Tsunemitsu S; Maeda K; Ando Y; Izumi N; Kimura M; Yamane N; Okuzono T; Morishita M; Kotani N; Kanda E; Deguchi M; Matsuguma K; Matsuki S; Hirota T; Irie S; Kusuhara H; Sugiyama Y
    J Clin Pharmacol; 2013 Jun; 53(6):654-61. PubMed ID: 23381882
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multidrug resistance protein 2 (MRP2) transports HIV protease inhibitors, and transport can be enhanced by other drugs.
    Huisman MT; Smit JW; Crommentuyn KM; Zelcer N; Wiltshire HR; Beijnen JH; Schinkel AH
    AIDS; 2002 Nov; 16(17):2295-301. PubMed ID: 12441801
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interaction of anti-HIV protease inhibitors with the multidrug transporter P-glycoprotein (P-gp) in human cultured cells.
    Washington CB; Duran GE; Man MC; Sikic BI; Blaschke TF
    J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Nov; 19(3):203-9. PubMed ID: 9803961
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-1 protease inhibitor saquinavir by grapefruit juice components.
    Eagling VA; Profit L; Back DJ
    Br J Clin Pharmacol; 1999 Oct; 48(4):543-52. PubMed ID: 10583025
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral coadministration of elacridar and ritonavir enhances brain accumulation and oral availability of the novel ALK/ROS1 inhibitor lorlatinib.
    Li W; Sparidans RW; Wang Y; Lebre MC; Beijnen JH; Schinkel AH
    Eur J Pharm Biopharm; 2019 Mar; 136():120-130. PubMed ID: 30660696
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modulation of P-glycoprotein function in human lymphocytes and Caco-2 cell monolayers by HIV-1 protease inhibitors.
    Profit L; Eagling VA; Back DJ
    AIDS; 1999 Sep; 13(13):1623-7. PubMed ID: 10509562
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Active apical secretory efflux of the HIV protease inhibitors saquinavir and ritonavir in Caco-2 cell monolayers.
    Alsenz J; Steffen H; Alex R
    Pharm Res; 1998 Mar; 15(3):423-8. PubMed ID: 9563072
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interactions of HIV protease inhibitors with ATP-dependent drug export proteins.
    Gutmann H; Fricker G; Drewe J; Toeroek M; Miller DS
    Mol Pharmacol; 1999 Aug; 56(2):383-9. PubMed ID: 10419558
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acute Effects of Viral Exposure on P-Glycoprotein Function in the Mouse Fetal Blood-Brain Barrier.
    Bloise E; Petropoulos S; Iqbal M; Kostaki A; Ortiga-Carvalho TM; Gibb W; Matthews SG
    Cell Physiol Biochem; 2017; 41(3):1044-1050. PubMed ID: 28222448
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibitory effect of human immunodeficiency virus protease inhibitors on multidrug resistance transporter P-glycoproteins.
    Shiraki N; Hamada A; Yasuda K; Fujii J; Arimori K; Nakano M
    Biol Pharm Bull; 2000 Dec; 23(12):1528-31. PubMed ID: 11145192
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Mathematical simulation to explain the coordinated functions of efflux and metabolism limiting the transport of anti-HIV agents across Caco-2 cells.
    Patel J; Hussain A; Pal D; Mitra AK
    Am J Ther; 2004; 11(2):114-23. PubMed ID: 14999363
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HIV protease inhibitor ritonavir: a more potent inhibitor of P-glycoprotein than the cyclosporine analog SDZ PSC 833.
    Drewe J; Gutmann H; Fricker G; Török M; Beglinger C; Huwyler J
    Biochem Pharmacol; 1999 May; 57(10):1147-52. PubMed ID: 11230802
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of placental P-glycoprotein: impact on indinavir transfer to the foetus.
    Sudhakaran S; Rayner CR; Li J; Kong DC; Gude NM; Nation RL
    Br J Clin Pharmacol; 2008 May; 65(5):667-73. PubMed ID: 18093255
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dose-dependent increase of saquinavir bioavailability by the pharmaceutic aid cremophor EL.
    Martin-Facklam M; Burhenne J; Ding R; Fricker R; Mikus G; Walter-Sack I; Haefeli WE
    Br J Clin Pharmacol; 2002 Jun; 53(6):576-81. PubMed ID: 12047481
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.